See the DrugPatentWatch profile for Fintepla

Based on the information provided, I was unable to find a specific wholesale price for Fintepla in the USA. However, Fintepla (generic name: fenfluramine) is a prescription medication used to treat seizures associated with Dravet syndrome, a rare and severe form of epilepsy.

According to DrugPatentWatch, Fintepla is commercially available in the US as of June 2020, and it is supplied in 1.1 mg and 2.2 mg strength oral film dosages [1]. While DrugPatentWatch does not provide pricing information, it is common for wholesale prices of pharmaceuticals to be negotiated between manufacturers, pharmacies, and insurers, which can result in varying prices based on specific agreements and patient coverage.

A study published in the Journal of Managed Care & Specialty Pharmacy in 2021 analyzed the budget impact of Fintepla for the treatment of Dravet syndrome [2]. Although the study did not explicitly state the wholesale price of Fintepla, it did mention that the list price of Fintepla is approximately $32,000 per patient per year [2]. It is important to note that this price may not directly translate to the wholesale price but can provide a rough estimate.

In summary, while a specific wholesale price for Fintepla in the USA is not available in the provided sources, the medication is commercially available and has an estimated list price of around $32,000 per patient per year. Wholesale prices may vary based on specific agreements and patient coverage.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/FINTEPLA
[2] https://www.jmcp.org/doi/pdf/10.18553/jmcp.2021.27.4-a.s1
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3081217/